 
 Clinical Trial Protocol : THR-1442 -C-481 
Study Title:  A Phase 1, Open -label, Randomized, Two -period, Two -treatment, 
Crossover Study to Evaluate the Effect of A High -Fat Meal on the 
Pharmacokinetics of Bexagliflozin in Healthy Subjects  
Study Number:  THR -1442 -C-481 
Study Phase:  1 
Product Name:  Bexagliflozin Tablets  
Indication:  Type 2 Diabetes Mellitus  
Investigators:  Single Center  
Sponsor:  Theracos Sub, LLC.  
Sponsor Contact:  Albert Collinson, Ph.D.  
Theracos Sub, LLC.  
225 Cedar Hill Stre et, Suite 200, Marlborough, MA 01752  
Phone: 508 -688-4221  
Sponsor’s 
Protocol 
Representative:  Xiao -Yan Li , Ph.D.  
Translational Medicine Group  
Massachusetts General Hospital  
185 Cambridge Street, Boston, MA 02114  
Phone: 617 -726-7960, Fax: 617 -643-8203  
Email : xli@ccib.mgh.harvard.edu  
Medical Monitor:  Geoffrey Walford, M.D.  
Massachusetts General Hospital  
185 Cambridge Street, Boston, MA 02114  
Phone: 617 -643-4986, Fax: 617 -643-8203  
E-mail: gwalford@partners.org . 
 
 Date 
Version 2: 20 May 2016  
Confidentiality Statement  
The information in this document is confidential information of Theracos Sub, LLC 
(“Theracos”) and must not be disclosed, used, or copied except with prior written approval 
from Theracos or to the ext ent required by applicable local, state or federal laws, rules and 
regulations . 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 2 of 48 SYNOPSIS  
Sponsor:  
Theracos Sub, LLC.  
Name of Finished Product:  
Bexagliflozin  Tablets  
Name of Active Ingredient:  
Bexagliflozin  
Name of Inactive Ingredient:  
Polyethylene oxide, glyceryl behenate, lactose monohydrate, micronized poloxamer 188, 
microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.  
Study Title:  
A Phase 1, Open -label, Randomized, Two -period, Two -treatment, Crossover Study to 
Evaluate the Effect of A High -Fat Meal on the Pharmacokinetics of Bexagliflozin in Healthy 
Subjects  
Study Number: THR -1442 -C-481 
Study Phase: 1 
Primary Objective:  
• To evaluate the effect of a high -fat meal on the pharma cokinetics  (PK)  of bexagliflozin  
extended release tablets  in healthy subjects . 
Secondary Objective s: 
• To evaluate the safety of bexagliflozin after a single oral dose in a fasted state and in a 
fed state in healthy subjects . 
• To evaluate the effect of a high -fat meal on the potential pharmacodynamic activity of 
bexagliflozin by determining urinary glucose excretion in healthy subjects  under fasted 
and fed conditions . 
Study Design:  
This is a phase 1, single center, open -label, 2 × 2 crossover study designed t o assess the 
effects of a high -fat meal on the PK of orally administered bexagliflozin tablets , 20 mg . 
Following a ≥ 10 -h overnight fast, eighteen (18) eligible healthy subjects will be assigned to 
two groups with an  equal number (n= 9) of subjects per grou p to receive a single oral dose of 
bexagliflozin  tablets,  20 mg , in either a fasted s tate or 30 min after starting a high -fat meal. A 
washout period of at least 7 days will be used between the two treatment periods, after which, 
subjects will receive bexag liflozin  tablets,  20 mg , in a fasted or fed state  (high -fat), 
whichever state they ha d not  received previously.  The h igh-fat meal will be ingested in its 
entirety over an approximate 25 -minute period, such that it is completed at least 5 minutes 
prior to t he scheduled time of bexagliflozin dosing for the group receiving bexagliflozin with 
food. If a portion of the meal is not consumed, the reason and the amount of remaining food 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 3 of 48 will be recorded. No food should be allowed for at least 4 h after drug adminis tration. 
Standard meals will be served to both groups 4 hour after dosing.  
In treatment period 1, subjects will be admitted to the clinic on day 0, the day before dosing, 
and will stay in the clinic until 48 -h post -dose. In treatment period 2, subjects wi ll be 
admitted to the clinic on day 7, the day before dosing, and will stay in the clinic until 48 -h 
post-dose. Blood samples for bexagliflozin plasma concentrations will be collected in each 
period at pre -dose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 3 6, and 48 h post -dose.  Urine 
collection in 12 h batches will be performed at pre -dose ( -12 to 0 h on day 0 and day 7 ), and 
at post -dose at 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h.  
Clinical laboratory tests and safety monitor ing will be conducted during both treatment 
periods.  
Study Population:  
Eighteen  healthy subjects are planned  to be enrolled and dosed . 
Diagnosis and Main Criteria for Inclusion  
1. Healthy subjects who are between the ages of 18 and 65 years, inclusive.  
2. Subjects with body -mass in dex (BMI) between 18.0 kg/m2 and 32.0 kg/m2, inclusive.  
3. Male s ubjects who are surgically sterile or male subjects who are not surgically sterile but 
who agree to refrain from donating sperm and use appropriate birth control such as the 
use of cond oms when engaging in sexual intercourse for a period of 30 days after 
discharge from the clinic.  
4. Female subjects of childbearing potential who are willing to use an adequate method of 
contraception and to not become pregnant for the duration of the study.  Female  subjects  
who are surgically sterile (hysterectomy, oophorectomy) or postmenopausal (absence of 
menses greater than 12 months and age > 45 years) are eligible if they test negative on 
the urine pregnancy test.  
5. Subjects wh o are non -smokers for at least 3  months prior to screening.  
6. Subjects with adequate venous access at multiple sites in both arms.  
Test Product; Dose; and Mode of Administration:  
Bexagliflozin tablets , 20 mg,  oral administration.  
Duration of Treatment:  
Two single d ose treatments with at lea st 7 days apart  
Pharmacokinetic Variables:  
The following PK parameters of bexagliflozin  will be determined  where feasible  after each 
subject is dosed with bexagliflozin  in a fasted state and 30  min after starting a high -fat meal . 
Cmax  Maximum observed plasma concentration  
Tmax   Time of maximum observed plasma concentration  
z        Terminal elimination phase rate constant  
T½        Apparent terminal elimination half-life 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 4 of 48 CL/F   Apparent oral clearance  
Vz/F  Apparent volume of distribution  
AUC 0-t  Area under the plasma concentration -time curve from Time 0 to Time t (time of last 
quantifiable plasma concentration)  
AUC 0-∞ Area under the plasma concentration -time curve from Time 0 to infinity  
Safety Assessments:  
• Vital signs  
• Clinical laboratory tests including blood chemistry and hematology parameters  
• Urinalysis  
• Adverse events  
• Concomitant medication use  
PD Assessment : 
• UGE  
• Urinary electrolytes, uric acid, and creatinine  
Statistical Methods:  
Statistical analysis will be performed using Statistical Analysis Software SAS for Windows® 
(SAS Institute Inc., USA). PK parameters of bexagliflozin  will be calculated by non-
compartme ntal analys is (NCA)  of plasma concentration -time data. Non-compartmental 
analysis  will be performed  using Phoenix® WinNonlin® 6.4 (Certara, USA). To assess the 
effect of  a high-fat meal  on the PK of bexagliflozin , an analyses of variance (ANOVA)  using 
a linear mixed -effects model will be fitted to the natural logarithmic transformation of PK 
parameters of bexagliflozin  (Cmax, AUC 0-t and AUC 0-∞). The linear mixed -effects model will 
include subject as a random effect, and treatment, period, and sequence as fi xed effects. The 
90% confidence intervals will be constructed for the fed : fasted ratio of geometric means of 
PK parameters ( Cmax, AUC 0-t and AUC 0-∞), with 80 -125% defined as the lack of interaction  
boundaries.  
Descriptive statistics for the PK parameters  Cmax, Tmax, AUC 0-∞, AUC 0-t , CL/F, V z/F, λz and 
terminal elimination half -life (T 1/2) will be tabulated by treatment. Means, standard 
deviations, medians, ranges  (min, max)  and geometric means and coefficients of variati on 
will be presented for all PK par ameters with exception of T max. Medians and ranges will be 
presented for T max. 
Descriptive statistics on the PD parameter s will be also performed.  The effect of high -fat 
meal on the cumulative UGE between subjects under fasted and fed conditions will be 
compared.   
Date of Original Protocol (V1) :  18 May 2016  
Prepared in:  Microsoft Word 2010  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 5 of 48 TABLE OF CONTENTS  
SYNOPSIS  ................................ ................................ ................................ ................................ .2 
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ ............ 8 
1 INTRODUCTION  ................................ ................................ ................................ ........... 11 
1.1 Bexagliflozin for the Treatment of Type 2 Diabet es Mellitus  ............................... 11 
1.2 Summary of Nonclinical Data with Bexagliflozin ................................ ................. 11 
1.3 Summary of Clinical Data with Bexagliflozin ................................ ....................... 11 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ....13 
2.1 Primary Objective  ................................ ................................ ................................ ..13 
2.2 Secondary Objectives ................................ ................................ ............................. 13 
3 INVESTIGATIONAL PLAN  ................................ ................................ .......................... 14 
3.1 Overall Study Design and Plan  ................................ ................................ .............. 14 
3.2 Rationale for Study Design  ................................ ................................ .................... 15 
3.3 Study Duration and Dates  ................................ ................................ ...................... 15 
4 STUDY POPULATION SEL ECTION  ................................ ................................ ........... 16 
4.1 Study Population  ................................ ................................ ................................ ....16 
4.2 Inclusion Criteria  ................................ ................................ ................................ ...16 
4.3 Exclusion Criteria  ................................ ................................ ................................ ..16 
5 STUDY TREATMENTS  ................................ ................................ ................................ .18 
5.1 Study Drug  ................................ ................................ ................................ ............. 18 
5.2 Treatments Administered  ................................ ................................ ....................... 18 
5.3 Selection and Timing of Dose for Each Subject  ................................ .................... 18 
5.4 Method of Assigning Subjects to Treatment Groups  ................................ ............. 19 
5.5 Blinding ................................ ................................ ................................ .................. 19 
5.6 Concomitant Therapy ................................ ................................ ............................. 19 
5.7 Restrictions  ................................ ................................ ................................ ............ 19 
5.7.1  Prior Therapy  ................................ ................................ ............................... 19 
5.7.2  Fluid and Food Intake  ................................ ................................ .................. 19 
5.7.3  Subject Activity Restrictions  ................................ ................................ .......20 
5.8 Treatment Compliance  ................................ ................................ ........................... 20 
5.9 Packaging and Labeling  ................................ ................................ ......................... 20 
5.10  Storage and Accountability  ................................ ................................ .................... 20 
6 STUDY PROCEDURES  ................................ ................................ ................................ .21 
6.1 Informed Consent ................................ ................................ ................................ ...21 
6.2 Medical History  ................................ ................................ ................................ .....21 
6.3 Physical Examination ................................ ................................ ............................. 22 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 6 of 48 6.4 Vital Signs  ................................ ................................ ................................ .............. 22 
6.5 Electrocardiography and Continuous Telemetry Monitoring  ................................ 22 
6.5.1  12-Lead Electrocardiograms  ................................ ................................ ........ 22 
6.6 Clinical  Laboratory Tests  ................................ ................................ ....................... 23 
6.6.1  Laboratory Parameters  ................................ ................................ ................. 23 
6.6.2  Sample Collection, Storage, and Shipping  ................................ .................. 24 
6.6.2.1  Hematology and Blood Chemistry ................................ ..................... 24 
6.6.2.2  Urinalysis  ................................ ................................ ........................... 24 
6.6.2.3  Urine Collection  ................................ ................................ ................. 24 
6.6.2.4  Plasma Sample Collection for PK  ................................ ...................... 24 
6.6.2.5  Blood and Urine Volume and Frequency for PK/PD and Safety 
Assessment  ................................ ................................ ......................... 24 
6.7 Pharmacokinetic Assessments  ................................ ................................ ............... 25 
6.8 Pharmacodynamic Assessment  ................................ ................................ .............. 26 
6.9 Adverse Events Assessments  ................................ ................................ ................. 26 
6.9.1  Collecting and Reporting Adverse Events  ................................ ................... 28 
6.9.2  Immediately Reportable Adverse Events  ................................ ..................... 28 
6.9.3  Pregnancy  ................................ ................................ ................................ .....29 
6.9.4  Follow -up of Adverse Events  ................................ ................................ ......29 
6.9.4.1 Follow -up of Non -serious Adverse Events  ................................ ........ 29 
6.9.4.2  Follow -up of Post -Study Serious Adverse Events  ............................. 30 
6.9.4.3  Hepatotoxicity  ................................ ................................ .................... 30 
6.9.4.4  Hypoglycemia  ................................ ................................ .................... 30 
6.10  Concomitant Medication Assessments  ................................ ................................ ..31 
6.11  Removal of Subjects from the Trial or Study Drug  ................................ ............... 31 
6.12  Appropriateness of Measurements  ................................ ................................ ......... 32 
7 STUDY ACTIVITIES  ................................ ................................ ................................ .....33 
7.1 Screening (Days -28 to -1) ................................ ................................ ..................... 33 
7.2 Clinic Admission (Day 0)  ................................ ................................ ...................... 33 
7.3 Day 1 Activities (Pre -dose)  ................................ ................................ .................... 34 
7.4 Day 1 Through 3 Activities (Post -dose)  ................................ ................................ 34 
7.5 Day 7 Activities  ................................ ................................ ................................ .....35 
7.6 Day 8 Activities (Pre -dose)  ................................ ................................ .................... 35 
7.7 Day 8 through 10 Activities (Post -dose)  ................................ ................................ 35 
7.8 Early Termination or Follow -up Procedures  ................................ ......................... 36 
8 QUALITY CONTROL AND ASSURANCE  ................................ ................................ .37 
9 PLANNED STATISTICAL METHODS  ................................ ................................ ........ 38 
9.1 General Considerations  ................................ ................................ .......................... 38 
9.2 Determination of Sample Size  ................................ ................................ ............... 38 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 7 of 48 9.3 Analysis Po pulations  ................................ ................................ .............................. 38 
9.4 Demographics and Baseline Characteristics  ................................ .......................... 38 
9.5 Statistical Analysis of Pharmacokinetic Variables  ................................ ................ 38 
9.6 Safety Analysis  ................................ ................................ ................................ ......39 
9.6.1  Adverse Events  ................................ ................................ ............................ 39 
9.6.2  Hypoglycemia  ................................ ................................ .............................. 40 
9.6.3  Clinical and Laboratory Events and Analyses  ................................ ............. 40 
9.6.4  Concomitant Medications  ................................ ................................ ............ 40 
9.7 Interim Analysis  ................................ ................................ ................................ .....40 
10 ADMINISTRATIVE CONSI DERATIONS  ................................ ................................ ....41 
10.1  Investigators and Study Administrative Struct ure ................................ ................. 41 
10.2  Institutional Review Board (IRB) or Independent Ethics Committee (IEC) 
Approval  ................................ ................................ ................................ ................ 41 
10.3  Ethical Conduct of the Study  ................................ ................................ ................. 41 
10.4  Subject Information and Consent ................................ ................................ ........... 42 
10.5  Subject Confidentiality  ................................ ................................ .......................... 42 
10.6  Study Monitoring  ................................ ................................ ................................ ...42 
10.7  Case Report Forms and Study Records  ................................ ................................ .43 
10.8  Protocol Violations/Deviations  ................................ ................................ .............. 43 
10.9  Access to Source Documentation  ................................ ................................ .......... 43 
10.10  Retention of Data  ................................ ................................ ................................ ...44 
10.11  Publication and Disclosure Policy  ................................ ................................ ......... 44 
11 REFERENCE LIST  ................................ ................................ ................................ ......... 45 
 
LIST OF IN -TEXT TABLES  
Table  1. Dosing Schedule  ................................ ................................ .......................... 18 
Table  2. Required Laboratory Tests  ................................ ................................ ........... 23 
Table  3. Blood and Urine Samples  ................................ ................................ ............ 24 
 
LIST OF APPENDICES  
Appendix 1  Schedule of Events  ................................ ................................ ............. 46 
Appendix 2  Sponsor Signatures ................................ ................................ ............. 47 
Appendix 3  Investigator’s Signature  ................................ ................................ .....48 
 
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 8 of 48 LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
AE adverse event  
ALB  albumin  
ALT  alanine aminotransferase  
ANOVA  analyses of variance  
AST  aspartate aminotransferase  
ATC  anatomic therapeutic chemical classification  
AUC  area under the time -concentration curve  
AUC extr extrapolated area under the plasma concentration -time curve  
AUC 0-t area under the plasma concentration -time curve from Time 0 to Time t  
BLOQ  below the limit of quantitation  
BMI  body mass index  
BP blood pressure  
BUN  blood urea nitrogen  
CFR  Code of Federal Regulations  
CK creatinine kinase  
Clast concentration corresponding to T last 
CL/F  apparent oral clearance  
Cmax maximum observed plasma concentrat ion 
CRF  case report form  
CRO  contract research organization  
d day 
ECG  electrocardiogram  
FDA  Food and Drug Administration  
FPG fasting plasma glucose  
GCP  Good Clinical Practice  
-GTP  gamma -glutamyl transferase  
h hour(s)  
HBsAg  hepatitis B surface an tigen  
HCO 3 bicarbonate  
Hct hematocrit  
HCV  hepatitis C virus  
HDL -C high density lipoprotein cholesterol  
Hgb hemoglobin  
HIV human immunodeficiency virus  
IC50 concentration that produces 50% inhibition of response  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 9 of 48 ICH International Conference on Harmo nisation  
IEC Independent Ethics Committee  
IND Investigational New Drug  
INR international normalized ratio  
IR immediate release  
IRAE  immediately reportable adverse event  
IRB Institutional Review Board  
K2EDTA  potassium ethylenediaminetetraacetic acid  
λz terminal elimination phase rate constant  
LDL -C low density lipoprotein cholesterol  
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
MCV  mean corpuscular volume  
MedDRA  Medical Dictionary for Regulatory Activities  
n number  
NCA  non compartmental analysis  
OTC  over-the-counter  
PD pharmacodynamic  
PE physical examination  
Pgp p-glycoprotein  
PK pharmacokinetic  
QRS  The QRS complex is a name for the combination of three of the graphical 
deflections seen on a typical elect rocardiogram  
QT C The corrected QT interval is a measure of the time between the start of the 
Q wave and the end of the T wave in the heart's electrical cycle  
RBC  red blood cell (count)  
RR respiration rate  
SAE  serious adverse event  
SD standard deviatio n 
SGLT 1 sodium glucose cotransporter 1  
SGLT2  sodium glucose cotransporter 2  
SOP standard operating procedure  
t1/2 apparent terminal elimination half -life 
TBL  serum total bilirubin  
TC total cholesterol  
TEAE  treatment emergent adverse events  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 10 of 48 TG triglycerides  
Tlast time of last measurable (positive) concentration  
Tmax time of maximum observed plasma concentration  
UGE  urinary glucose excretion  
UGT1A9  UDP glucuronosyltransferase 1 family, polypeptide A9  
ULN  upper limit of normal (value)  
UTI urinary  tract infection  
Vz/F apparent volume of distribution  
WBC  white blood cell (count)  
WHO -DD World Health Organization Drug Dictionary  
WOCBP  women of childbearing potential  
z Terminal elimination phase rate constant  
 
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 11 of 48 1 INTRODUCTION  
Bexagliflozin, a pote nt and selective renal Na+/glucose transport protein  sodium glucose 
cotransporter 2  (SGLT2 ) inhibitor is being developed as a treatment for type 2 diabetes 
mellitus. The transport of glucose from the renal tubule into the tubular epithelial cells is 
facili tated by SGLT2 which is expressed primarily in the kidney in the early proximal tubule 
of the nephron  (Washburn 2009 ). By inhibiting SGLT2, bexagliflozin blocks th e 
reabsorption of filtered glucose, in turn promoting urinary glucose excretion and thereby 
reducing plasma glucose (Zhang, Welihinda et al. 2011 ). 
Clinical pharmacok inetic  (PK)  studies have shown that the peak plasma bexagliflozin 
concentration s occurred between 3 to 5 h  and thereafter declined in a biphasic manner  with 
mean elimination half -life values ranging from 7.80 to 9.71 h . Bexagliflozin is cleared 
predominant ly by metabolism to an inactive metabolite, bexagliflozin 3 -O-glucuronide by  
the uridine diphosphate glucuronosyltransferase isoform 1A9 (UGT1A9) pathway . Extended  
release bexagliflozin tablet formulations are developed to provide greater than 75% release in 
approximately 8 h in vitro . The objective of this study is to evaluate the effects of a high -fat 
meal  on the  PK of  extended release bexagliflozin  tablets,  20 mg . 
1.1 Bexagliflozin  for the Treatment of Type 2 Diabetes Mellitus  
Bexagliflozin  is a highly speci fic inhibitor of SGLT2 with an in vitro  IC50 of 2 nM or 
0.9 ng/mL and a 2435 -fold selectivity for human SGLT2 compared with sodium glucose 
cotransporter 1  (SGLT1 ). Details of the nonclinical and clinical findings are described in the 
Investigator’s Brochur e. 
1.2 Summary of Nonclinical Data with Bexagliflozin  
Bexagliflozin exhibits high permeability and is a potential Pgp  (p-glycoprotein)  substrate and 
inhibitor. It is not a si gnificant inducer or inhibitor of cytochrome P450 isozymes and other 
transporters relevant for drug -drug interactions.  
1.3  Summary of Clinical Data with Bexagliflozin  
The early clinical studies have been conducted using immediate release (IR) products in 
capsules. Theracos has completed multiple phase 1 studies to evaluate safety , tolerability , 
pharmacokinetics (plasma exposure), pharmacodynamics (glucosuria) , and drug metabolism 
in healthy subjects, patients with type 2 diabetes, and diabetic patients with renal impairment .  
Following administration of bexagliflozin IR capsules, time of maximu m observed plasma 
concentration  (Tmax) was reached  within 1 to 3  h. The systemic exposure was dose 
proportional with a maximum observed plasma concentration  (Cmax) of 11  ng/mL  per mg 
bexagliflozin and an area under the plasma concentration -time curve (AUC 0-24) of 
approximately 60  ng·h/mL per mg bexagliflozin in healthy or diabetic subjects.  Following 
administration of bexagliflozin tablets in extended release formulations, T max was reached 
between 3 to 5 h. The tablets produced dose proportional exposure wi th a C max of 4 or 8 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 12 of 48 ng/mL per mg bexagliflozin and an AUC 0-24 of 40 or 50 ng·h/mL per mg bexagliflozin in 
healthy subjects  when dosing was before or after a meal, respectively.  
The principal metabolites in humans are  similar to those found in monkeys and a re 
dominated by glucuronid es of the parent compound , for which the AUC is >30% relative to 
parent bexagliflozin. Modest accumulation consistent with an extended half -life has been  
seen following multiple daily dosing. Following oral administration of radio labeled 
bexagliflozin, >90% of the ingested radioactivity was recovered, 51% as fecal excretion and 
41% as urinary excretion. In urine, bexagliflozin accounts for 1.5% of the dose; most of the 
radioactivity is excreted as bexagliflozin 3’ -O-glucuronide. Th e largest fraction of the 
radioactivity in feces is due to bexagliflozin, accounting for about 30% of the administered 
dose.  
The safety and tolerability of bexagliflozin in healthy or diabetic subjects was initially 
evaluated in a single -dose study of up t o 100 mg, followed by a 4 -week treatment study in 
which doses ranged from 5 mg/d to 50 mg/d. The most frequently occurring adverse events 
(AEs) were mild to moderate headache, pollakiuria, nausea, and fatigue. No symptomatic 
hypoglycemia was reported and n o treatment -related adverse event led to discontinuation of 
treatment. Extended release tablets of 3 mg to 90 mg strengths were well tolerated in a 
Japanese population with few adverse events reported.  
Detailed information of bexagliflozin  clinical experie nce and potential risks for study 
subjects are provided in the Investigator’s Brochure.  
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 13 of 48 2 STUDY OBJECTIVES  
2.1 Primary Objective  
To evaluate the effect of a high -fat meal on the pharmacokinetics of bexa gliflozin  extended 
release tablets in healthy subjects . 
2.2 Secondary Objectives  
To evaluate the safety  of bexagliflozin  after a single oral dose in fasted or fed state in healthy 
subjects . 
To evaluate the effect of a high -fat meal on the potential pharmacodynamic activity of 
bexagliflozin by determining urinary glu cose excretion in healthy subjects  under fasted and 
fed conditions . 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 14 of 48 3 INVESTIGATIONAL PLAN  
3.1 Overall Study Design and Plan  
This single center, phase 1, open -label, 2 × 2 crossover study is designed to assess the effects 
of a high -fat meal on the PK of orally a dministered bexagliflozin tablets . Eighteen  eligible 
healthy subjects will be randomized into two groups such that an equal number (n= 9) of 
subjects will  receive a single oral dose of a bexagliflozin  tablet s, 20 mg,  with or without a 
meal  on treatment day 1. Subjects randomized to receive bexagliflozin tablets  with a high -fat 
meal  on day 1 will receive a second dose of  bexagliflozin tablets  without a meal  on treatment 
day 8 after an overnight fast. Subjects randomized to  receive bexagliflozin tablets  withou t a 
meal on treatment day 1 after an overnight fast will receive a second  dose of bexagliflozin 
tablets  with a high -fat meal  on treatment day 8.  
Bexagliflozin will be taken orally with 240 mL of water in the morning (approximately  8 
a.m. to 10 a.m.). The t ime of dosing for a given subject will be the same (as far as  
practicalities permit) in both treatment periods.  
The high-fat meal will follow the FDA guidance (Food Drug Administration 2002 ) on high -
fat (50% of total caloric content of the meal) and high -calori c (800 to 1000 cal) content . An 
example of the high -fat meal would be two eggs fried in butter , two strips of bacon, two 
slices of toast with butter, four ounces of hash brown potatoes and eight ounces of whole 
milk. Substitutions in this meal can be made as long as the meal provides a similar amount of 
calories from protein, carbohydrate, and fat and has comparable meal volume and viscosity.  
Subjects dosed in the fed state will receive  an oral bexagliflozin tablet s, 20 mg,  30 min after 
starting to  consume a high-fat meal after an overnight fast . No additional food should be 
allowed for at least 4 h  post-dose. Water will be allowed as desired  except for one hour 
before and after drug administration. The meal will be ingested  in its entirety over an 
approximate 25 -minute period, such that it is completed at least 5  minutes prior to the 
scheduled time of bexagliflozin  dosing for the fed state treatment. If a portion of the meal is 
not consumed, the reason and the amount of remaining food  will be recorded.  Subjects 
should receive standard  meals scheduled at the same time in each period of the study.  
Subjects dosed in the fasting s tate will receive a n oral bexagliflozin tablet s, 20 mg , after an 
overnight  fast. No food should be allowed for at least 4 h post -dose.  Water will be allowed as 
desired except for one hour before and  after drug administration.  Subjects should receive 
standard meals scheduled at the same time in each period of the study.  
Subjects will be admitted to the clinic on day 0 and day 7, the day before  dosing  in each 
treatment period , and will stay in the clinic until 48 -h post -dose. Standa rd meals will be 
served at  the clinic during the stay. Blood samples ( 2 mL) for bexagliflozin  plasma 
concentrations will be collected at 0 h (pre -dose), and at , 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 
and 48 h post -dose (days 1-3 in treatment period 1  and days 8-10 in treatment period 2 
respectively ). Urine collection in 12 h batches will be performed at pre -dose ( -12 to 0 h on 
day 0 and day 7 ), and at post -dose at 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h.  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 15 of 48 Clinical laboratory tests and safety moni toring will be conducted during both treatment 
periods.  
For the Schedule of Events  table, see Appendix 1 . For the overall Dosing Schedule, see Table 
1. 
3.2 Rationale for Study Design  
The PK profile of bexagl iflozin formulated as an extended  release product at 10 and 30 mg 
has been evaluated in an early clinical trial (THR -1442 -C-445). The effects of dose 
administration in the fasted and fed states were assessed in healthy  Japanese subjects for 
absorption, dis tribution, metabolism and excretion of bexagliflozin . Twelve s ubjects were 
randomized evenly to two dose groups ( 10 and 30 mg ). Each group received first dose of 
bexagliflozin tablet s under fed state on day 1, then after 7 -day washout, subjects received 
second dose under fasted state . The administration of bexagliflozin at 10 and 30 mg with a 
standard meal resulted in increased average C max (range 39% to 59% for bexagliflozin and 
19% to 28% for bexagliflozin 3 -O-glucuronide) and decreased half -life (range 2 3-40% for 
bexagliflozin and 10% to 21% for bexagliflozin 3 -O-glucuronide ). However, no meaningful 
change in the T max of either analyte was observed.  No effect of  food on the overall systemic 
exposure [area under the plasma concentration -time curve (AUC) ] of bexagliflozin  and 
bexagliflozin 3 -O-glucuronide  was observed .  
In general, meals that are high in total calories and fat content are more likely to affect the 
gastrointestinal  physiology and thereby result in a maximal effect on the bioavailability of a 
drug substance.  Therefore, a high -fat meal will be used in this study  to evaluate the potential 
maximum effect of food on the PK of bexagliflozin tablets , 20 mg, which is the intended 
commercial product . The planned sample size in this crossover study will  be powered to 
provide sufficient data for a statistical test ing of food effect on the PK of bexagliflozin. T he 
results will provide  a guide for the timing of dosing relative to meals for this bexagliflozin  
product.  
3.3 Study Duration and Dates  
This is a phase  1, two -period, two -treatment, crossover study. Subjects will be screened 
within  28 days of the initiation of study drug dosing. Eligible subjects who consent to the 
study will be randomly assigned to 1 of 2 groups , each group will receive both treatments 
alternately, in a crossover fashion (two -period, two -treatment crossover design), with the two 
treatment periods separated by a 7-day washout period .  
In treatment period 1, subjects will be admitted to the clinic on day 0, the day before dosing, 
and will stay in the clinic until 48 h post -dose. In treatment period 2, subjects will be 
admitted to the clinic on day 7, the day before dosing, and will stay in the clinic until 48 h 
post-dose. The scheduled visits and procedures  for each visit are provided in Appendix 1 . 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 16 of 48 4 STUDY POPULATION SEL ECTION  
4.1 Study Population  
Eighteen eligible he althy subjects who consent to participate in this study will be enrolled.  
4.2 Inclusion Criteria  
Each subject must meet the following criteria to be enrolled  in this study.  
1. Subjects who are between 18 -65 years  of age  inclusive  with bo dy-mass index (BMI) 
between 18 .0 kg/m2 and 3 2.0 kg/m2, inclusive . 
2. Male s ubjects  who are surgically sterile or male subjects who are not surgically sterile 
must agree to refrain fr om donating sperm and use appropriate birth control such as the 
use of condoms when engaging in sexual intercourse for a period of 30 days a fter 
discharge from the clinic . 
3. Female subjects of childbearing potential who are willing to use an adequate method of 
contraception and to not become pregnant for the duration of the study.  
4. Female  subjects  who are surgically sterile (hysterectomy, oophorectomy) or 
postmenopausal (absence of men ses greater than 12 months and age > 45 years) are 
eligible if they test negative on the urine pregnancy test.  
5. Subjects who are non -smokers for at least 3 months prior to screening . 
6. Subjects with adequate venous access at multiple sites in both arms . 
7. Subje cts who are willing and able to be confined to the clinical research facility as 
required by the protocol . 
8. Subjects who have the ability to comprehend and willingness to provide written informed 
consent in accordance with institutional and regulatory guide lines . 
 
4.3 Exclusion Criteria  
Subjects who meet any of the following criteria will be excluded from the study.  
1. Subjects who are determined by the investigator or sub -investigator to be unsuitable for 
participating in the study based on medical conditions, inc luding impairment of the 
central nervous system, circulatory system, respiratory system, blood/hematopoietic 
function system, gastrointestinal system, liver/kidney function, thyroid function, pituitary 
function and/or adrenal function . 
2. Female subjects who are nursing or pregnant.  
3. Subjects with a clinically significant history of allergy to drugs or latex . 
4. Subjects with a history of alcohol or drug dependence  in the last 12 months . 
5. Subjects who had 400 mL of whole blood collect ed within four months or 200 mL  of 
whole blood collect ed within one month of the screening test . 
6. Subjects who had blood component collection within 14 days prior to the screening test . 
7. Subjects who have used prescription or over -the-counter (OTC) drugs within 14 da ys 
prior to the first dose. 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 17 of 48 8. Subjects who have used vitamin preparations or supplements (including St. John ’s Wort  
and ginseng ) within 14 days prior to the first dose . 
9. Subjects who have undergone strenuous activity within 72 hours prior to Day 1 in each 
period.  
10. Subjects who are unable (e.g., food intolerance) or unwilling to consume a high -fat 
breakfast within 25 minutes.  
11. Subject s who ha ve been treated with an investigational drug  within 30 days or 7 half -
lives of the investigational drug, whichever is longer, prior to the first dose of study drug 
in this trial . 
12. Subjects who had previously received EGT0001474 or bexagliflozin , or any other 
SGLT2 inhibitors  within 3 months from the screening . 
13. Subject s whose screening electrocardiogram  (ECG ) demonstrates any one of the 
following: he art rate > 100 bpm, QRS > 120 msec, QTc > 470 msec  (corrected by 
Bazett’s formula) , PR > 220 msec  (a subject with PR > 220 msec will generally be 
excluded but exceptions may be allowed at the discretion of the investigator), or any 
rhythm that is not sinus  rhythm, sinus brad ycardia, or sinus arrhythmia . 
14. Subject s whose sitting blood pressure is above 140/90 mmHg at screening . 
15. Subjects who have a positive result of HBsAg antigen , HCV  antibody , urinary drug or 
urinary cotinine test. 
16. Subjects with known human immunodeficiency virus ( HIV) disease . 
17. Subjects with abnormal vital signs , laboratory values , symptoms or signs that are deemed 
clinically significant by the investigator.  
18. Subject s who have had a febrile illness within 5 days prior to the f irst dose of study 
medication . 
19. Subjects vaccinated within 30 days prior to the first dose of medication . 
20. Detectable urine glucose at screening  (trace or greater ). 
21. Subjects with eGFR  < 90 mL/min/1.73  m2 or a history of kidney transplant . 
22. Subjects with digestion problems , including gastroesophageal reflux disease, irritable 
bowel syndrome, gastroparesis, and any other disorder deemed by the investigator to be 
clinically significant . 
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 18 of 48 5 STUDY TREATME NTS 
5.1 Study Drug  
Bexagliflozin tablet s, 20 mg, are blue caplet -shaped, film -coated tablets that are intended for 
use in investigational studies in humans. The tablets contain excipients designed to promote 
extended release through a gastroretentive mechanism . The active tablets exhibit a greater 
than 75% release of drug substance by 8 hour s in simulated gastric fluid in vitro . 
5.2 Treatments Administered  
Subjects who consent to be in the study will be randomly assigned to 1 of 2 treatment groups. 
Each group will be dosed with bexaglifloz in under a fasted state in one period and under a 
fed state  (high fat, high calorie)  in the other period. A single o ral dose of bexaglifloz in 
tablet s, 20 mg, will be provided to subjects in each treatment period.  
The detailed dosin g schedule is shown in Table 1 . 
Table  1. Dosing Schedule  
Subject 
Group  
 Treatment Period  Treatment Period 1  
(Day 1)  Treatment Period 2  
(Day 8)  
Dosing Time (h)  -0.5 0 4 -0.5 0 4 
Group 1  Bexagliflozin  single 
oral dose   X   X  
*Meal  X  X   X 
Group 2  Bexagliflozin  single 
oral dose   X   X  
*Meal    X X  X 
*High -fat meal will be provided at time -0.5 h , while standard meal will be provided at other times . 
 
5.3 Selection and Timing of Dose for Each Subject  
Dosing order with bexaglifl ozin alone or in combination with food will be based on 
randomized assignment. Results from previous clinical trials indicate that doses of 1.7 mg to 
100 mg of bexagliflozin  are well tolerated and the planned dose of bexagliflozin tablet s, 20 
mg, produced significant glucosuria and is not expected to produce serious drug -related 
adverse events.  
• Bexagliflozin  alone : After an overnight fast of at least 10 h, a bexagliflozin  tablet s, 20 
mg, will be administered 4 h prior to the first meal of the day with 240 m L of water.  
• Co-administration of bexagliflozin  with food : After an overnight fast of at least 10 h, a 
bexagliflozin  tablet s, 20 mg , will be administered 30 min after starting to  consume a 
high-fat meal  with 240 mL water . 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 19 of 48 If for some reason, a portion of th e water  is not consumed, the reason and the amount of 
remaining water  will be recorded.  
5.4 Method of Assigning Subjects to Treatment Groups  
A sufficient number of subjects will be screened to ensure that up to 18 subjects will be 
randomized. E ligible subject s will be randomly assigned to group 1 or group 2 in a 1:1 ratio.  
Subjects who discontinue the study after randomization for non -safety related reasons may be 
replaced  to ensure that t he nu mber of evaluable subjects in each group should not be less than 
8. 
5.5 Blinding  
This is an open -label study. There is no blinding process in this protocol.  
5.6 Concomitant Therapy  
The participants are not allowed to take any prescription or non -prescription drugs, vitamins, 
or dietary supplements at any time during 14 days prior  to (first) drug administration and for 
the duration of each study period.  No other concomitant medications are permitted with the 
exception of those required for treatment of an adverse event. Subjects may receive any 
medications for adverse events that are necessary to control or minimize the likelihood of 
more serious adverse events in the investigators’ judgment.  
Concomitant medications administered at the time of randomization and during the study are 
to be recorded on the case report form ( CRF ). The medication name, dose, frequency, route 
of administration, date(s) of administration and reason for administration must be recorded.  
This documentation should continue until 1 week from the end of the last study product 
dosing .  Medications that a subject  receives after entering the study and prior to 
randomization must be recorded in the CRF.  
5.7 Restrictions  
5.7.1  Prior Therapy  
No study subject shall have been dosed  with any SGLT2 inhibitor within 3 months  prior to 
the screening, nor an investigational drug within  30 days or 7 half -lives, or used any 
prescription medication or herbal supplements within 14 days prior to the first dose of study 
medication.  
5.7.2  Fluid and Food Intake  
An overnight fast of at least 10 h prior to dosing is required. For the fasting state trea tment 
group, oral intake of food (standard meals) will be restricted for 4  h following administration 
of bexagliflozin .  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 20 of 48 The fed state treatment wil l consist of a bexagliflozin tablet, 20 mg,  taken 30 min after  
subjects  start to consume a high -fat (approxi mately 50% of total caloric content of the meal), 
high-calorie (approximately 800 –1000 cal) meal  after an overnight fast.  
Each dose will be administered with 240 m L tap water. Food intake will be forbidden during 
the first 4 h post dosing. Water can be al lowed as desired except for one hour before and after 
drug administration  
Subjects  are expected to consume 100% of the high-fat meal and 240 mL of water provided.  
If a portion of the meal and water is not consumed, the reason and the amount of remaining 
meal and water will be recorded.   
Subjects should receive standard  meals scheduled at the same time in each period of the 
study.  
5.7.3  Subject Activity Restrictions  
Light physical activity is permitted . Subjects should not perform strenuous activity during the 
clinical stay and during the washout period as this could result in elevations of muscle 
creatin ine kinase (CK) levels. Smoking during the study is prohibited.  
5.8 Treatment Compliance  
To ensure compliance, all medication dosing will be supervised by the Investig ator or 
qualified staff in the clinic. The exact times of medication dosing will be recorded in the 
CRFs, including a record of checks followed by hand mouth inspection.  
5.9 Packaging and Labeling  
Investigational product will be provided to the pharmacist or d esignated site personnel in 
bottles of 90 tablets enclosed with a child -resistant cap. The pharmacist or designated site 
personnel will dispense the investigational products for each subject according to 
randomization assignment . 
5.10 Storage and Accountability  
Bexagliflozin tablets  should be stored at controlled room temperature , 15 to 30°C (59 to 
86°F)  in a secure area with access limited to authorized personnel. The drug storage facility 
must comply with the medication storage instructions.  The trial staff mu st record the amount 
of investigational product dispensed to each subject in the dosing record.  A full reconciliation 
of drug inventory will be performed at the end of the study and the results of this inventory 
must be recorded in the Drug Accountability Form. All unused drug must be returned to a 
sponsor -designated depot after drug accounting is verified by the sponsor or its designee.  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 21 of 48 6 STUDY PROCEDURES  
6.1 Informed Consent  
Before each subject is enrolled in the clinical study, written informed consent will be  
obtained from the subjects according to the regulatory and legal requirements. As part of this 
procedure, the investigator or designee must explain orally and in writing the nature, duration, 
and purpose of the study, and the action of the drug in such a manner that the study subject is 
aware of the potential risks, inconveniences, or AEs that may occur. The investigator should 
educate potential subjects about the scientific importance of their data and the vital role that 
their participation has for the o utcome of the entire study. The subject must be informed that 
he/she is free to withdraw from the study at any time. He/She will receive all information that 
is required by federal regulations and International Conference on Harmonisation (ICH) 
guidelines.  
The informed consent document must be signed and dated; one copy will be given to the 
subjects, and the investigator will retain a copy as part of the clinical study records. The 
investigator will not undertake any investigation specifically required for the clinical study 
until written consent has been obtained. The terms of the consent and when it was obtained 
must also be documented.  
6.2 Medical History  
The following information will be collected at the screening visit: 
• Demographic information including age , sex, and race and whether childbearing potential 
if female . 
• Significant medical, surgical history and timeframe of the history relative to study 
screening, if applicable.  
• Clinically significant h istory of allergy including drugs and latex . 
• History of smo king, alcohol or drug dependence , or abuse  in the last 12 months . 
• Any blood donation or blood component donation within 4 months . 
• Use of any medications including over the counter drugs, vitamins, or dietary 
supplements within 14 days . 
• History of vaccinati on within 30 days prior to the first dose of study medication . 
• History of diagnosis with HIV, hepatitis B  or hepatitis  C. 
• Use of any investigational drug in the previous 30 days or 7 half-lives, wh ichever is 
longer . 
• Prior exposure to bexagliflozin  (or EGT0001474) , or any other SGLT2 inhibitors within 
3 months from the screen ing. 
 
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 22 of 48 6.3 Physical Examination  
The investigator or designated qualified individual will perform the physical examination s 
(PEs) . A complete physical examination will be performed at screening  and at the 
termination  visit. Partial physical examinations will be performed at scheduled visits . 
A complete physical examination will include measurement of body weight and height 
(height will  be measured only at screening), general assessment of all body systems including 
the skin, head, eyes, ears, nose, throat, neck, lungs, heart, abd omen, lymph nodes, and 
extremities. A partial physical examination will include body weight and an update of the 
general assessment of the skin, heart, lungs and abdomen.  
6.4 Vital Signs  
Vitals signs, including pulse, systolic and diastolic blood pressure  (BP)  in a seated  position  
will be obtained after a subject has been sitting for 5  min, respiration rate  (RR) , and  oral 
temperature , will be measured at  the scheduled visits described in Appendix 1 . BP measures 
will be obtained using a calibrated sphygmomanometer . 
Vital signs should be measured prior to blood draws.  
Respirat ion rate should  be measured after at least 5 min of rest. Devices designed to measure 
BP from the finger or wrist may not be used . 
6.5 Electrocardiography and Continuous Telemetry Monitoring  
6.5.1  12-Lead Electrocardiograms  
A 12 -lead electrocardiogram (ECG) will be conducted as li sted in Appendix 1  and whenever 
clinically indicated.  
This procedure should be performed in the supine position after at least 10 min of rest. ECG 
parameters measured will be the RR interval, PR interval, QRS duration, and QT. Each ECG 
should also be assessed by the investigator for signs of ischemia, clinically significant 
hypertrophy, and clinically significant T -wave abnormalities.  
It is the investigator  or designee ’s responsibility to review the results of the ECG as they 
become available. For each abnormal ECG result, the investigator needs to ascertain if this is 
a clinically significant change from the screening ECG for that individual subject (this 
determination, however, does not necessarily need to be made the first tim e an abnormal 
result is observed. The investigator may repeat the ECG to verify the results of the original 
result). If the ECG result is determined to be a clinically significant and abnormal change 
from baseline for that subject, this is considered an AE . 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 23 of 48 6.6 Clinical Laboratory Tests  
6.6.1  Laboratory Parameters  
Subjects will be in a seated  or supine position during blood collection . Clinical blood 
chemistry and hematology  will be performed at the scheduled visits ( Appendix 1 ).  Blood 
samples should be drawn after overnight fasting prior to breakfast . The details of the required 
laboratory tests are listed in Table 2 . 
Table  2. Required Laboratory Tests
Test Name   Blood or urine  
Vol. (mL)  
Hematology 3 (blood)  
Hematocrit (Hct)  
Hemoglobi n (Hgb)  
Mean corpuscular hemoglobin (MCH)  
Mean corpuscular hemoglobin concentration 
(MCHC)  Mean corpuscular volume (MCV)  
Platelet count  
Red blood cell (RBC) count  
White blood cell (WBC) count with 
differential   
Serum Chemistry and Electrolytes  10 (seru m) 
Albumin (ALB)  
Alanine aminotransferase (ALT)  
Aspartate aminotransferase (AST)  
Blood urea nitrogen (BUN)  
Glucose  
Bicarbonate (HCO 3) 
Creatinine Chloride (Cl)  
Total protein  Calcium (Ca)  
Magnesium  
Phosphorus  
Potassium (K)  
Sodium (Na)  
Total bilirubin  
Direct  bilirubin  
Uric acid   
Serum Lipids  6 (serum)  
Total cholesterol (TC)  
High -density lipoprotein cholesterol (HDL -C) 
Triglycerides (TG)  Low-density lipoprotein cholesterol (LDL -
C), calculated  
  
Urinalysis  10 (urine)  
Appearance  
Bilirubin  
Color  
Glucose  
Ketones 
Microscopic examination of sediment  Nitrite  
Occult blood  
pH 
Protein  
Specific gravity  
Urobilinogen  
Leukocyte esterase   
Urine Collection (in 12 -h batches)  
Glucose  
Creatinine  
Sodium   
Potassium  
Calcium  
Uric acid  All (urine)  
Urine drug screen  10 (urin e) 
Amphetamines  
Barbiturates  
Cocaine Metabolites  
Cotinine  Opiates  
Benzodiazepines  
Cannabinoids   
Urine pregnancy test    2 (urine)  
Infectious Disease Testing  6 (serum)  
Hepatitis B surface antigen ( HBsAg ) Hepatitis C virus ( HCV )   
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 24 of 48 6.6.2  Sample Collection, Storage, and Shipping  
6.6.2.1  Hematology and Blood Chemistry  
Blood samples for hematology and chemistry will be collected. Timing of collection is 
described in Appendix 1 . 
6.6.2.2  Urinalysis  
Clean -catch, midstream urin e samples will be collected per schedule outlined in Section 7  
and in Appendix 1 . Dipstick urinalysis will be conducted.  Microscopy will be obtained if the 
subject has a positive result on any of the dipstick  tests that require microscopic follow -up to 
clarify their significance.  In addition, urinalysis will be performed from clean catch urine 
sample at any time in subjects with symptoms of urinary tract infection (UTI) or 
pyelonephritis.  
6.6.2.3  Urine Collection  
Pre-dose urine samples must be collected from -12 to 0 h for baseline measurement, 
immediately after which subjects will empty their bladders.  Post dose urine will be collected 
without preservative in four (4) batches: 0 to 12 h, 12 to 24 h , 24 to 36 h, and 36 to 48 h 
collections.  Urine must be refrigerated at 2 -8oC during collection.  After collection, the total 
volume of each batch and collection time will be recorded.  A 20 mL aliquot will be prepared 
from well mixed urine collections . The samples  will be analyzed for  urinary glucose  (PD) , 
uric acid, creatinine, and electrolytes.  
6.6.2.4  Plasma Sample Collection for PK  
Whole venous blood samples of 2 mL will be collected from a peripheral vein  in each period 
at pre -dose and a t 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post -dose. Samples will be 
placed in tubes containing potassium ethylenediaminetetraacetic acid  (K2EDTA ) and stored 
on ice until centrifuged under refrigeration for at least 10 min at 3,000 rpm. After 
centrifugation, plasma will be removed and stored frozen in 3 aliquot s of 200 L at or below 
-20°C. Processed frozen plasma samples will be transferred on dry ice to the analytical 
laboratory and will be stored at or below -20oC until analysis.  
6.6.2.5  Blood and Urine Volume and Frequen cy for PK /PD and Safety Assessment  
The total volume and number of sampling times for blood and urine collections are outline d 
in Table 3 . 
Table  3. Blood and Urine Samples  
Test Volume/sample (mL)  No. of Samples  Total  Storage  
Blood     
Hematology  3 6 18  
Chemistry  16 6 96  
Infectious Disease Testing  6 1 6  
PK 2 28 56 ≤ -20oC 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 25 of 48 Table  3. Blood and Urine Samples  
Test Volume/sample (mL)  No. of Samples  Total  Storage  
Urine Collection      
Urinalysis  10 6 60 +4oC 
PD 20 10 200 +4oC 
Urine Drug Screen  10 1 10  
Urine Pregnancy Test  2 1 2 +4oC 
Total blood volume required in each subject: 1 76 mL; total urine volume required in each subject: 272 mL.  
 
6.7 Pharmacokinetic Assessments  
A non -compartmental analysis  (NCA)  will be used to calculate the PK parameters of 
bexagliflozin using the software Phoenix® WinNonlin® 6.4 (Certara, USA) . From the plasma 
bexagliflozin concentration -time data, the following PK para meters will be estimated for 
each subject where feasible.  
Cmax Maximum observed plasma concentration  
Tmax Time of maximum observed plasma concentration  
z      Terminal elimination phase rate constant  
T½     Apparent terminal elimination half life  
CL/F  Ap parent oral clearance  
Vz/F  Apparent volume of distribution  
AUC 0-t      Area under the plasma concentration -time curve from Time 0 to Time t (time of 
last quantifiable plasma concentration)  
AUC 0-∞ Area under the plasma concentration -time curve from Time 0 to infinity  
Cmax and Tmax will be obtained directly from experimental observations. If multiple maxima 
occur at equal concentrations, the first temporal value will be taken.  
The apparent terminal elimination half-life, T1/2, where determinable, will be cal culated as 
the natural log of  2 divided by the terminal phase rate constant, λ z. The number of data points 
included in the regression will be determined by visual inspection, but a minimum of three 
data points in the terminal phase, excluding C max, is required to estimate λ z. In order for the 
selection to take place the adjusted r2 value reported in Phoenix®WinNonl in® must be above 
0.7.  
AUC 0-t and AUC 0-∞ will be calculated using the linear trapezoidal  linear interpolation  
method , using actual elapsed time values. If the actual collection time is unknown the 
nominal c ollection time may be used for the purposes of PK parameter estimation. For the 
purpose of calculating AUC, all missing values will be treated as missing in the PK analysis 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 26 of 48 and excluded from analysis except when they occur at pre -dose where they will be se t to 
zero. All values that were below the limit of quantitation (BLOQ) prior to Tmax will be set to 
zero. BLOQ values that occur after T max will be set to missing. W hen ≥ 2 consecutive plasma 
concentrations below the limit of quantitation (BL OQ) are  encountered after Tmax, these and 
all subsequent values will be excluded from the analysis.  
AUC 0-∞ will be calculated according to the following equation:  
AUC 0-∞= AUC last + (Clast / λz), where C last is the last temporal quantifiable plasma 
concentration  corresponding to T last. 
The proportion of AUC 0-∞ due to extrapolation (AUC extr) will be calculated  and expressed as 
a percentage. AUC 0-∞ values will be considered unreliable es timates if the AUC extr is greater 
than 20%.  
CL/F will be calculated as Dose/AUC 0-∞. 
Vz/F will be calculated as Dose/(λ z × AUC 0-∞). 
T½ will be calculated as 0.693/λ z. 
Descriptive statistics for the plasma concentrations of bexagliflozin  by Treatment and 
Timepoint will be provided. A listi ng of plasma concentrations by SubjectID, Treatment 
Period and T imepoint will also be provided.  
6.8 Pharmacodynamic Assessment  
Urinary glucose excretion will be determined as the pharmacodynamic  (PD) parameter at 
baseline (day 0  and day 7), and up to 48 h postdose (days 1 -3 and 8 -10). The effect of high -
fat meal will be evaluated by comparing the mean c umulative urinary glucose excretion  
(UGE ) between subjects under fasted and fed conditions. Potential effects on urinary 
creatini ne, uric acid, sodium, potassium, and calcium will also be analyzed.  
6.9 Adverse Events Assessments  
Adverse event (AE ): Any untoward medical occurrence in clinical investigation subject 
administered a pharmaceutical product. An AE does not necessarily have to have a causal 
relationship with this treatment.  
 
An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the use of a 
medicinal product, whether or n ot considered related to the medicinal product.  
Serious adverse event (SAE): A serious adverse event (experience) or reaction is any 
untoward medical occurrence that at any dose:  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 27 of 48 • results in death,  
• is life -threatening,  
• (NOTE: The term "life -threatening" in the definition of "serious" refers to an event in 
which the patient was at risk of death at the time of the event; it does not refer to an event 
which hypothetically might have caused death if it were more severe.)  
• requires inpatient hospitalization or pro longation of existing hospitalization,  
• results in persistent or significant disability/incapacity, or  
• is a congenital anomaly/birth defect , 
• is an important medical event.  
 
An important medical event is an event that may not be immediately life -threatening  or result 
in death or hospitalization but may jeopardize the patient or may require intervention to 
prevent one of the other outcomes listed in the definition above. Examples of such events are 
intensive treatment in an emergency room or at home for aller gic bronchospasm; blood 
dyscrasias or convulsions that do not result in hospitalization; or development of drug 
dependency or drug abuse.  
Non-serious adverse events are all events that do not meet the criteria for a "serious" adverse 
event.  
Immediately Rep ortable Adverse Event (IRAE):  Any serious adverse event or any 
adverse event that necessitates discontinuation of study drug.  
Clinical Laboratory Changes:  It is the investigator’s responsibility to review the results of 
all laboratory tests as they become available. For each abnormal laboratory test result, the 
investigator needs to ascertain if this is a clinically significant change from baseline for that 
individual subject. (This determination, however, does not necessarily need to be made the 
first time  an abnormal value is observed. The investigator may repeat the laboratory test or 
request additional tests to verify the results of the original laboratory tests). If this laboratory 
value is determined to be an abnormal change from baseline for that subj ect, this is 
considered an AE.  
Hypoglycemia will be defined as any FPG  (fasting plasma glucose)  value < 70 mg/dL and 
documented as described in Section 6. 9.4.4. 
Any increase in liver function tests (AST, aspartate aminotran sferase (ALT ), or bilirubin) 
greater than 3 times the upper limit of normal ( ULN ) for the laboratory utilized will be 
considered a clinical -laboratory adverse event.  
An increase in creatinine from baseline by 0.5 mg/dL or more will be reported as a laborat ory 
adverse event.  
Severity:   Adverse events will be graded on a 3 -point scale and reported as indicated on the 
CRF.  The intensity of an adverse experience is defined as follows:  
1 = Mild: discomfort not  iced, but no disruption to daily activity;  
2 = Mode rate: discomfort sufficient to reduce or affect normal daily activity;  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 28 of 48 3 = Severe: inability to work or perform normal daily activity.  
 
Study Drug Causality:  The site and database should ask for the causality relative to the 
study compound.  Relationship of  an adverse event to dosing will be assessed as follows:  
Definite: There is a reasonable causal relationship between the study drug and the AE when 
the event responds to withdrawal of the study drug (dechallenge), and recurs with rechallenge 
by administrat ion of the study drug.  
Probable: There is a reasonable causal relationship between the study drug and the AE. The 
event responds to dechallenge. Rechallenge is not required.  
Possible: There is a reasonable causal relationship between the study drug and the  AE. 
Dechallenge is lacking or unclear.  
Not Likely: There is a temporal relationship to study drug administration, but there is not a 
reasonable causal relationship between the study drug and the event.  
Unrelated: There is not a temporal or causal relation ship to study -drug administration.  
6.9.1  Collecting  and Reporting Adverse Events  
The investigator will periodically assess subjects for the occurrence of adverse events. To 
avoid bias in collecting  information about  adverse events , the investigator should ask 
subjects  the following question: "How have you felt si nce you were last checked ?" All 
adverse events (serious and non -serious) reported by the subject must be recorded on the 
source documents and CRFs provided by the sponsor.  
In addition, Theracos’ Medical M onitor or its designated personnel must be notified 
immediately by telephone or fax of any immediately reportable adverse events according to 
the procedure outlined below. Special attention should be paid to recording hospitalization 
and concomitant medica tions.  
6.9.2  Immediately Reportable Adverse Events  
The investigator must report any serious adverse ev ent (SAE), by telephone, email, or fax, to 
Theracos or its representative  immediately after the investigator becomes aware of the event.  
An immediately reporta ble adverse event ( IRAE ) form should be completed and sent by  
email or  fax or overnight courier to the sponsor within 24 h of knowledge of the event . 
Non-serious events that require discontinuation of study drug (including laboratory 
abnormalities) should be reported to Theracos  within 3 working days. The IRAE form should 
be completed and sent by email or fax or overnight courier to the sponsor.  
Subjects experiencing an SAE  should be followed clinically until their health has returned to 
baseline status or until all parameters have returned to normal, or have otherwise been 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 29 of 48 explained. It is expected that the investigator will provide or arrange appropriate supportive 
care for the subject.  
6.9.3  Pregnancy  
Women of childbearing potential (WOCBP) who are sexually act ive must use an effective 
method of birth control during the course of the study, in a manner such that risk of failure is 
minimized.  
Before enrolling WOCBP in this clinical trial, investigators must review guidelines about 
study participation for WOCBP. T he topics should generally include:  
1. General information . 
2. Informed consent form . 
3. Pregnancy prevention information . 
4. Drug interactions with hormonal contraceptives.  
5. Contraceptives in current use.  
6. Guidelines for the follow -up of a reported pregnancy.  
 
Prior to  study enrollment, WOCBP must be advised of the importance of avoiding pregnancy 
during trial participation and the potential risk factors for an unintentional pregnancy. The 
subject must sign an informed consent form stating the above -mentioned risk facto rs and that 
the consequences were discussed with her.  
During the study, all WOCBP should be instructed to contact the investigator immediately if 
they suspect they might be pregnant (e.g. , missed or late menstrual cycle).  
If a subject or investigator suspe cts that the subject may be pregnant prior to investigational 
product administration, the investigational product administration must be withheld until the 
results of serum pregnancy tests are available. If the pregnancy is confirmed, the subject must 
not receive the investigational product and must not remain in or be enrolled in the study.  
The investigator must notify the Medical Monitor within 3 working days of the receipt of 
information that any female subject who has become  pregnant. This reporting req uirement 
will continue until 4 weeks after the last investigational product exposure.  
The investigator must record the event on the Pregnancy Surveillanc e form and forward it to 
the sponsor’s clinical or designated personnel.  
6.9.4  Follow -up of Adverse Events  
6.9.4.1  Follow-up of Non -serious Adverse Events  
Non-serious adverse events that are identified on the last scheduled contact must be recorded 
on the AE CRF wi th the current status noted. All non -serious events that are ongoing at the 
time will be recorded as ongoing  on the CRF.  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 30 of 48 6.9.4.2  Follow -up of Post -Study Serious Adverse Events  
SAEs  that are identified on the last scheduled contact must be recorded on the AE CRF page 
and reported to Theracos  according to the reporting procedures outlined in Section 6. 9.1. 
These may include unresolved previously reported SAEs , or new SAEs . The investigator 
should follow these subjects  until the  events are resolved, or the subject is lost to follow -up. 
Resolution means the subject has returned to  the baseline state of health, or the investigator 
does not expect any further improvement or worsening of the subject’s condition. The 
investigator should continue to report any significant follow -up information to Theracos  until 
the event has been resolv ed. 
Any new SAEs  reported by the subject to the investigator that occur after the last scheduled 
contact, and are determined by the investigator to be reasonably associated with the use of 
the study drug, should be reported to the Medical Monitor or the sp onsor’s d esignated 
personnel . These may include SAEs  that are captured on follow -up telephone contact or at 
any other time point after the defined study period (i.e., up to last scheduled contact). The 
investigator should follow subjects with  SAEs identifi ed after the last scheduled contact until 
the events are resolved, or the subject is lost to follow -up. The investigator should continue 
to report any significant follow -up information to the Sponsor until the event has been 
resolved.  This study requires t hat subjects be actively monitored for SAEs for  at least 14 days 
after discharge from the study . 
6.9.4.3  Hepatotoxicity  
Any clinically significant increase in hepatic enzymes and specifically ALT or AST ≥ 3x 
ULN requires immediate repeat test within 48 to 72 h to confirm the hepatic enzyme 
elevation. Study medication should be stopped and the event should be reported as an 
adverse event within the CRF if the enzyme elevation is confirmed or worsening. Potential 
contributors to hepatic enzyme elevation should be eva luated by the investigator. The 
investigator is encouraged to consult with the Medical Monitor regarding ongoing diagnostic 
workup.  
Study drug should be permanently discontinued if any of the following criteria is met:  
• ALT or AST > 8xULN;  
• ALT or AST > 3xUL N and (TBL > 2xULN or INR > 1.5);  
• ALT or AST > 3xULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>  5%).  
6.9.4.4  Hypoglycemia  
Hypoglycemia will be recorded under 5 categories:  
• Critical  hypoglycemia :  An event requiring assistance of another person to actively 
administer carbohydrate, glucagons, or other resuscitative actions. These episodes may be 
associated with sufficient neuroglycopenia to induce seizure or coma. Plasma glucose 
measu rements may not be available during such an event, but neurological recovery 
attributable to the restoration of plasma glucose to normal is considered sufficient 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 31 of 48 evidence that the event was induced by a low plasma glucose concentration. All such 
events sho uld be recorded as serious adverse events in the CRF.  
• Documented symptomatic hypoglycemia:  An event during which typical symptoms of 
hypoglycemia are accompanied by a measured plasma glucose concentration ≤ 70 mg/dL 
(3.9 mmol/L).  
• Asymptomatic hypoglycemia:  An event not accompanied by typical symptoms of 
hypoglycemia but with a measured plasma glucose concentration ≤ 70 mg/dL 
(3.9 mmol/L).  
• Probable symptomatic hypoglycemia:  An event during which symptoms of 
hypoglycemia are not accompanied by a plasma glucose determination but that was 
presumably caused by a  plasma glucose concentration ≤ 70 mg/dL (3.9 mmol/L) . 
• Relative hypoglycemia:  An event during which the person with diabetes reports any of 
the typical symptoms of hypoglycemia, and interprets those as indicative of 
hypoglycemia, but with a measured plasm a glucose concentration > 70 mg/dL 
(3.9 mmol/L).  
 
6.10 Concomitant Medication Assessments  
A concomitant medication is any medication the subject enters the trial taking and is 
expected to continue taking for some portion of the trial, as well as any medication the 
subject takes during the course of the trial. All prescription and over -the-counter medications, 
including vitamins and herbal supplements, that subjects receive during the trial must be 
documented on the CRF. This documentation should continue until t he subjects are 
discharged.  
Concomitant medications will be coded using the World Health Organization Drug 
Dictionary (WHO -DD). A table of concomitant medications based on the anatomic 
therapeutic chemical classification (ATC) and preferred name will be pr oduced. A listing of 
concomitant medications will include all medications taken by any subjects during the course 
of the study.  
Concomitant medications administered during the study are to be recorded on the CRF. The 
medication name, dose, frequency, route  of administration, date(s) of administration and 
reason for administration must be recorded. This documentation should continue until 
discharge from the study.  
6.11 Removal of Subjects from the Trial or Study Drug  
The investigator must emphasize to potential s ubjects the importance of continued 
participation for the full duration of the trial during the informed consent process.  
Participation in the study is voluntary. A participant has the right to withdraw from the study 
at any moment for any reason. The inve stigator will be informed immediately.  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 32 of 48 The investigator has the right to terminate participation of a subject in case it is difficult to 
obtain blood samples, in case of violation of the protocol or in case of severe or serious 
adverse events.  
In case a su bject withdraws from the study, the study monitor will be informed immediately. 
If there is a medical reason for withdrawal, the volunteer should remain under the 
supervision of the medical investigator until satisfactory health returns.  
Subjects who disco ntinue the active dosing  phase of the study due to adverse event(s) or 
other safety concerns will not be replaced.  
When the decision is made to discontinue a subject’s participation in the study, no further 
study drug medication should be administered. Eve ry attempt should be made to complete all 
required study evaluations and procedures. Reasons for all withdrawals should be recorded 
on the CRF . 
The investigator may withdraw a subject from THR -1442 -C-481 trial for any of the 
following reasons:  
• A protocol v iolation occurs,  
• A serious or intolerable adverse event occurs,  
• A clinically significant change in a laboratory parameter occurs,  
• The sponsor or investigator terminates the study, or  
• The subject requests to be discontinued from the study.  
 
Subjects who do not complete the study but who have received investigational product 
should have a follow -up examination, including a complete physical examination, vital signs, 
ECG and clinical laboratory tests if clinically indicated according to Section 7 . 
6.12 Appropriateness  of Measurements  
PK and safety parameters in this protocol are standard assessments and are widely used and 
generally recognized as reliable, accurate, and relevant measurements.  
Determination of urinary glucose is  a non -invasive and quantitative method that allows 
immediate assessment  of the pharmacodynamic effects of an SGLT2 inhibitor.  The excreted 
glucose is dose dependent, saturable, and correlates with lowering of fasting plasma glucose 
and of hemogl obin A1c based on data from bexagliflozin  studies and other SGLT2 inhibitors.  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 33 of 48 7 STUDY ACTIVITIES  
7.1 Screening (Day s -28 to -1) 
During the screening period, the following information will be gathered and the indicated 
procedures will be performed:  
• Explain the co ntent of informed consent to the subject and collect signed informed 
consent.  
• Medical history and demographic information obtained.  
• Perform a physical examination, including height and weight measurements as described  
in Section 6.3.  
• Vital signs collected including: pulse, temperature, respiratory rate, and blood pressure 
taken in the sitting position after at least 5 min of rest as described in Section 6.4 . 
• 12-lead ECG taken in the s upine position after at least 10 min of rest as described in 
Section 6.5 . 
• Clean -catch, mid -stream urine will be collected for urinalysis  as described in Section 
6.6.2.2 . If urine is dipstick positive for leukocyte esterase  or nitrites , sample is to be sent 
for microscopic evaluation and culture.  
• Urine screen for drug abuse  and cotinine . If the drug screen is conducted more than 5 
days pre -dose, the drug screen must be rep eated prior to dosing. Drug abuse testing 
includes amphetamines, barbiturates, cocaine metabolites, opiates, benzodiazepines, an d 
cannabinoids . 
• Women will receive  urine pregnancy test. 
• Blood will be drawn for hematology, s erum chemistry, and serology as detailed in 
Section 6.6.2.1.  
• The inclusion/exclusion criteria will be evaluated based on the information collected at 
the screening examination.  
 
7.2 Clinic Admission (Day 0) 
• On day 0 the following information will be gathered and the indicated procedures will be 
performed:  
• If screening was conducted more than five days prior to dosing, the inclusion and 
exclusion criteria must be confirmed and a urine drug screen performed . 
• A partial physical examination must be performed as described in Section 6.3 . 
• If the subject is still eligible based on the study inclusion and exclusion criteria the 
subject will be admitted and randomized into the study.  
• Conco mitant medications and adverse event information will be collected as appropriate  
• Pre-dose urine collection in 12 h batches at -12 h to 0 h (on day 0) for baseline analysis of 
electrolytes, uric acid and creatinine and for UGE (PD) analysis as described in  
Section  6.6.2. 3. 
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 34 of 48 7.3 Day 1 Activities  (Pre-dose)  
The following information will be gathered and the indicated procedures will be performed 
Pre-dose: 
• Record vital signs pre-dose.  
• Perform 12 -lead ECG taken in  the supine position after at least 10 min of rest pre -dose.  
• Complete pre -dose urine collection at 0 h ( -12 h to 0 h) for baseline UGE analysis and 
analysis of electrolytes, uric acid and creatinine analysis as described in Section  6.6.2.3 . 
• Urine sample will be prepared for pre -dose urinalysis as described in  Section 6.6.2.2 . If 
urine is dipstick positive for leukocyte esterase or nitrites , sample is to be sent fo r 
microscopic evaluation and culture.  
• Pre-dose blood will be drawn for hematology, and serum chemistry as detailed in Section 
6.6.2.1.  
• Pre-dose plasma samples will be drawn for PK analysis as detailed in Section 6.6.2. 4. 
• Pre-dose concomitant medications and adverse event information collected as 
appropriate.  
 
7.4 Day 1 Through 3 Activities  (Post -dose)  
• For group 1 subjects, after an overnight fast of at least 10 h, bexagliflozin  tablets,  20 mg , 
will be administ ered 30 min after the start of the high-fat meal as detailed in  Section 5.2.  
• For group 2 subjects, after an overnight fast of at least 10 h, bexagliflozin  tablets,  20 mg , 
will b e administered 4 h prior to the first meal of the day as detailed in  Section 5.2.  
• Record vital signs at 4 h (day 1) and 48 h (day 3) post -dose.  
• Perform 12 -lead ECG taken in the supine position after at least 10 min of rest at 4 h (day 
1) post -dose.  
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2. 4 at 1, 2, 3, 4, 
5, 6, 8, 10, 12, 16, 24,  36 (day 2) and 48 h ( day 3). 
• Urine collec tion in 12 h batches at 0 to 12 h and 12 to 24 h, 24 to 36 h and 36 to 48 h for 
analysis of electrolytes, uric acid and creatinine and for UGE (PD) analysis as described 
in Section  6.6.2.3 . 
• Post-dose conc omitant medications and adverse event information is collected as 
appropriate.  
• On day 3 urine will be collected as described in Section 6.6.2.2  for urinalysis.  
• On day 3 blood will be drawn for hematology and serum chemistry a s detailed in Section 
6.6.2.1.  
• After completion of all day 3 activities the subject will be discharged and scheduled for 
day 8 (period 2 ) of the study.  
 
Subjects who are terminated from the study for any reason after  dosing has started must have 
the information and procedures shown for day 8 collected and completed and the reason for 
termination entered onto the case report form.  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 35 of 48 7.5 Day 7 Activities  
On day 7 the following information will be gathered and the indicated pr ocedures will be 
performed:  
• If the subject is still eligible based on the study inclusion and exclusion criteria, the 
subject will be admitted for the cross -over phase of the study.  
• Concomitant medications and adverse event information will be collected as  appropriate.  
 
Pre-dose urine collection in 12 h batches at -12 h to 0 h (day 1) for baseline analysis of 
electrolytes, uric acid and creatinine and for UGE (PD) analysis as described in Section 
6.6.2. 3. Subjects who are terminated from the study at this time must have the reason for 
termination entered onto the case report form.  
 
7.6 Day 8 Activities  (Pre-dose)  
On day 8 the following information will be gathered and the indicated procedures will be 
performed Pre-dose: 
• Record vital signs pre -dose.  
• Perform 12 -lead ECG taken in the supine position after at least 10 min of rest pre -dose.  
• Complete pre -dose urine collection at 0 h ( -12 h to 0 h) for baseline UGE analysis and 
analysis of electrolytes, uric acid and c reatinine analysis as described in Section 6.6.2.3  
• Urine will be collected pre -dose as described in Section 6.6.2.2  for urinalysis.  
• Pre-dose blood will be drawn for hematolog y and serum chemistry as detailed in Section 
6.6.2.1.  
• Pre-dose plasma samples will be drawn for PK analysis as detailed in Section 6.6.2. 4. 
• Concomitant medica tions and adverse event information is collected as appropriate.  
 
 
7.7 Day 8 through 10 Activities  (Post-dose ) 
• For group 1 subjects, a fter an overnight fast of at least 10 h, bexagliflozin  tablets,  20 mg , 
will be administered 4 h prior to the first meal of the  day as detailed in  Section 5.2.  
• For group 2 subjects, a fter an overnight fast of at least 10 h, bexagliflozin  tablets,  20 mg , 
will be administ ered 30 min after the start of the high -fat meal as detailed in  Section 5.2.  
• Record vital signs at 4 h (day 8) and 48 h (day 10) post -dose.  
• Perform 12 -lead ECG taken in the supine position after at least 10 min of rest at 4h (day 
8) and 48 h (day 10) post -dose.  
• Plasma samp les will be drawn for PK analysis as detailed in Section 6.6.2.4   at 1, 2, 3, 4, 
5, 6, 8, 10, 12, 16, 24 (day 9), 36 (day 9) and 48 h (day 10).  
• Urine collection in 12 h batches at 0 to 12 h and 12 t o 24 h, 24 to 36 h and 36 to 48 h for 
analysis of electrolytes, uric acid and creatinine and for UGE (PD) analysis as described 
in Section 6.6.2.3 .Concomitant medications and adverse event information is collected as 
appropriate.  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 36 of 48 • On day 10 perform a physic al examination as described in Section 6.3 . 
• On day 10 , urine will be collected as described in Section 6.6.2.2  for urinalysis.  
• On day 10 , blood will be drawn for hematology and serum che mistry as detailed in 
Section 6.6.2.1.  
• After completion of all day 10 activities the subject will be discharged .  A follow up visit 
may be scheduled on day 15 if clinically indicated . If a subject who withdraws conse nt 
prior to completion of all study activities, a follow up visit may be scheduled if clinically 
indicated.  
 
7.8 Early Termination  or Follow -up Procedures  
Subjects who have completed study activities or have withdraw n consent and have received 
investigational product should have a follow -up examination  if clinically indicated , including 
a complete physical examination, vital signs, ECG, and clinical laboratory tests (hematology, 
serum chemistry, and glycemic control). The sponsor must be notified in the event t hat a 
subject withdraws or has been withdrawn from the study.  
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 37 of 48 8 QUALITY CONTROL AND ASSURANCE  
The clinical research facility will be monitored by the study monitor to ensure correct 
performance of the study procedures and assure that the study will be condu cted according to 
the protocol and relevant regulatory requirements. CRF entries will be verified with the 
source documentation.  
Quality control principles will be applied throughout the performance of this study by 
following the standard operating procedu re (SOPs ) of the contract research organization 
(CRO ) and the sponsor. Review procedures will be implemented at the CRO for all 
documents that are generated in relation to the study.  
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 38 of 48 9 PLANNED STATISTICAL  METHODS  
9.1 General Considerations  
The statistical evalu ation of PK parameters wil l be conducted by the  designated CRO.  A 
detailed Statistical and Analytical Plan will be generated prior to initiation of the study.  
Statistical analysis will be performed using Statistical Analysis Software SAS for Windows® 
(SAS Institute Inc.,  USA).  Non-compartmental analysis will be performed using Phoenix® 
WinNonlin® 6.4 (Certara, USA).  
9.2 Determination of Sample Size  
The sample size for this study is not based upon formal statistical consideration. The sample 
size is considered a dequate to characterize the PK of bexagliflozin, to assess potential food -
drug interactions , and to provide safety and tolerability data on bexagliflozin when 
administered with food (Food and Drug Administration 2002).  
9.3 Analysis Populations  
Statistical anal ysis populations will include:  
Safety:  The Safety Population will include all randomized subjects who receive at least one 
dose of the drug . Subjects will be analyzed according to the treatment received . 
PK: The PK  Population will include all randomized su bjects who receive study drug and 
who have sufficient plasma bexagliflozin  measurements to derive at least one PK parameter 
following dosing.  The PK Population will be  used to summarize the PK  parameters.  
9.4 Demographics and Baseline Characteristics  
Baseline characteristics including demographics, physical examination, ECG parameters, and 
safety laboratory values will be summarized for all subjects in the Safety and the PK 
Populations. Descriptive statistics will be performed.  
9.5 Statistical Analysis of Pharmacok inetic Variables  
To assess the  effect of a high-fat meal on the PK of bexagliflozin , an analyses of variance 
(ANOVA)  using a linear mixed -effects model will be fitted to the natural logarithmic 
transformation of PK parameters of bexagliflozin  (Cmax, AUC 0-t and AUC 0-∞). The linear 
mixed -effects model will include subject as a random effect, and treatment, period, and 
sequence as fixed effects. The 90% confidence intervals will be constructed for the  fed: 
fasted ratio of the least squares (LS) geometric means of PK p arameters ( Cmax, AUC 0-t and 
AUC 0-∞), with 80 -125% defined as the lack of interaction boundaries.  
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 39 of 48 Descriptive statistics for the PK parameters  Cmax, Tmax, AUC 0-∞ , AUC 0-t , CL/F, Vz/F, λz, and 
terminal elimination half-life (T1/2) will be tabulated by trea tment. Means, standard 
deviations, medians, ranges  (min, max)  and g eometric means and coefficients of variation 
will be  presented for all PK parameters with the exception of T max. Medians and ranges will 
be presented for Tmax.  
A listing of derived PK para meters of bexagliflozin by SubjectID and Treatment Period will 
be provided.   
Descriptive statistics on the PD parameter s will be also performed.  The effect of high -fat 
meal on the cumulative UGE between subjects under fasted and fed conditions will be 
comp ared.   
9.6 Safety Analysis  
Safety data will include adverse events (AEs), physical exam results, vital signs, ECG 
results, and clinical lab results, including serum chemistry, hematology, and urinalysis. 
Observed data will be described as counts and percentag es for discrete variables and 
estimation of means, standard deviations ( SDs), medians, inter -quartile range, minimum and 
maximum for continuous metrics. All subjects in the Safety Population will be included in 
the safety analyses. All safety data will be presented in by -subject listings and included in the 
clinical trial report.  
9.6.1  Adverse Events  
Adverse events will be mapped to preferred term and body system using the Medical 
Dictionary for Regulatory Activities (MedDRA). The number and percentage of subject s 
reporting adverse events will be determined by relationship to treatment and by severity of 
the event. Drug -related adverse events will be considered those to be possibly related to 
bexagliflozin  administration.  
Adverse event listings will be provided fo r the following subsets:  
• all treatment emergent AEs ( TEAEs ). 
• all TEAEs at least possibly related to bexagliflozin . 
• serious TEAEs (if any) . 
• TEAEs leading to study discontinuation (if any).  
 
AEs are dosing  emergent if they occur on or after bexagliflozin  administration.  TEAEs will 
be considered at least possibly related to bexagliflozin  based on the investigator’s  
assessment . Only TEAEs will be tabulated in summary tables.  If the AE (s) onset date -time or 
date occurs after the first dose  up until right before the next dose, the AE (s) will be assigned 
to the first treatment. Any AE (s) that occur after the second dose up until the follow -up visit 
will be assigned to the second treatment.  
Tabulations will display TEAEs by severity and relationship to bexagliflozin . 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 40 of 48 9.6.2  Hypoglycemia  
Hypoglycemia as defined in Section 6. 9.4.4 will be presented in listings and summarized.  
9.6.3  Clinical and Laboratory Events and Analyses  
Clinical and laboratory metrics are measured at baseline and during the tre atment  periods  
(Appendix 1 ). These variables include vital signs (blood pressure, respiration, temperature), 
clinical laboratory results (see Section 6.6  for a com plete list), and ECGs.  
Serum chemistry,  hematology , and urinalysis (quantitative parameters)  data will be 
summarized for each treatment period . Summaries for change from baseline will be 
presented for these laboratory tests. In addi tion, all seru m biochemistry, h ematology , and 
urinalysis data outside the reference ranges  will be summar ized by parameter . 
Laboratory data will be summarized using Low -Normal -High shift tables. ECG results will 
be summarized as changes from baseline in intervals. Abnor malities as well as changes from 
previous assessment will be listed.  
9.6.4  Concomitant Medications  
Concomitant medications will be coded using the World Health Organization Drug 
Dictionary (WHO -DD). A by -subject listing of concomitant medications will include al l 
medications taken during the study.  
9.7 Interim Analysis  
There will be no interim analysis conducted.  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 41 of 48 10 ADMINISTRATIVE CONSI DERATIONS  
10.1 Investigators and Study Administrative Structure  
Information regarding key personnel involved in the conduct of the study, in cluding names 
and contact details of participating investigators, monitors, clinical laboratories, and technical 
departments and/or institutions, as well as information on members of additional study 
committees, will be found in the study files of the investigational site . 
10.2 Institutional Review Board  (IRB) or Independent Ethics Committee 
(IEC) Approval  
The study protocol, informed consent document, relevant supporting information, and all 
types of subject recruitment or advertisement information must be subm itted to the IRB /IEC  
for review and must be approved by the sponsor and the IRB /IEC  before the study is 
initiated.  Any amendments or addenda to the protocol must also be approved by the 
IRB/IEC  prior to implementing changes in the study. The investigator is responsible for 
keeping the IRB /IEC  informed  of the progress of the study and of any changes made to the 
protocol as deemed appropriate. The investigator must also keep the IRB /IEC  informed of 
any SAEs occurring to subjects under their supervision.  
10.3 Ethical Conduct of the Study  
The procedures set out in this protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that the sponsor and investigator follow  
Good Clinical Practice  (GCP)  Guidelines and the guiding principles detailed in the 
Declaration of Helsinki. The study will also be carried out in keeping with applicable local 
laws and regulations. An inspection by the sponsor representatives and/or their designee 
and/or healthy authority or other authorized re gulatory authorities  representatives may occur 
at any time. The investigator must agree to the inspection of study -related records by the 
regulatory authority /sponsor representatives, and must allow direct access to source 
documents to the regulatory autho rity/sponsor representatives.  
The investigator is responsible for complying with the protocol and all appropriate 
regulations and guidelines governing global clinical research. Additionally, he/she is 
responsible for ensuring that all participating staff m embers are adequately trained and 
competent to perform his/her assigned tasks.  
Modifications to the study protocol will not be implemented by either the sponsor or the 
investigator without agreement by both parties. However, the investigator may implement a 
deviation from or a change of the protocol to eliminate any immediate hazards to the trial 
subjects without prior IRB /IEC  or sponsor approval/favorable opinion. As soon as possible, 
the implemented deviation or change, the reasons for it, and if appropri ate, the proposed 
protocol amendment should be submitted to the head of the investigational site, IRB (via the 
head of the investigational site) /sponsor.  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 42 of 48 Any deviations from the protocol must be fully explained and documented by the 
investigator. The circ umstances, action taken, and impact of the deviation on the trial must be 
communicated by the principal investigator to the designated medical monitor.  Any 
subsequent actions will be assessed by the designated medical monitor and documented.  
10.4 Subject Infor mation and Consent  
The Investigator  will draft the informed consent form based on the protocol  and CRO’s draft 
informed consent form . The sponsor will review the investigator’s draft informed consent 
form  prior to submission to the IRB /IEC  and the final IR B/IEC approved document must be 
provided to the sponsor for regulatory purposes.  
Prior to the beginning of the study, the investigator must have received from the Ethics 
Committee or IRB the written approval  or favorable opinion of the informed -consent for m 
and any other written information to be provided to subjects.  The written approval of the 
IRB/IEC  together with the approved subject information/ informed consent forms must be 
filed. The informed consent form must contain all elements required by the F DA under 21 
CFR Part 50 and the ICH GCP Guidelines (E6) , in addition to, any other elements required 
by regulations  or institutional policy.  
Written informed consent must be obtained before any study -specific procedure takes place. 
Participation in the stu dy and date of informed consent given by the subject should be 
documented appropriately in the subject’s files. A copy of the signed informed consent form 
must be provided to the subject. If applicable, it will be provided in a certified translation in 
the language understood by the subject, if not English. Signed consent forms must remain in 
each subject’s study file and must be available for verification by study monitors at any time.  
10.5 Subject Confidentiality  
The information obtained during the conduct of this clinical study is confidential, and 
disclosure to third parties other than those noted below is prohibited. Information obtained 
during the conduct of this study will be used by the sponsor in connection with the 
development of the study drug. The stu dy investigator is obliged to provide the sponsor with 
complete test results and all data developed in this study. Subject -specific information may 
be provided to other appropriate medical personnel only with the subject’s permission. To 
ensure compliance with current ICH guidelines, data generated by this study must be 
available for inspection upon request by representatives of national and local health 
authorities, the sponsor, and the IRB /IEC  for each study site.  
Subject names and other identifiers, such  as photographs, audio, or videotapes, may not be 
disclosed in any publication without prior written authorization from the subject.  
10.6 Study Monitoring  
An authorized sponsor representative will conduct site visits to inspect study data, subjects’ 
medical rec ords, and CRFs in accordance with ICH guidelines, GCPs, and the respective 
national and local government regulations and guidelines.  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 43 of 48 The investigator will permit authorized representatives of the sponsor and the respective 
national or local health authorit ies, other authorized regulatory authorities,  and IRB/IEC  to 
inspect facilities and records relevant to this study.  
10.7 Case Report Forms and Study Records  
For each subject consented, a case report form (CRF), in paper or electronic format, will be 
supplied an d maintained by the CRO staff and signed by the investigator or authorized 
designee to indicate that he/she has reviewed and agrees with the entered data. This also 
applies to those subjects who fail to complete the trial. The reason a subject is withdrawn  
must be recorded in the case report form.  
Entries made in the CRF must be verifiable against source documents. Source documents are 
defined as all medical records, medical notes, laboratory results, ECG traces and any 
additional document other than the CR F that has original subject information contained 
within it.  
All CRFs and source documents should be completed following GCPs and the CRO’s 
standard operating procedures.  
10.8 Protocol Violations/ Deviations  
It is important to conduct the study according to the protocol. Protocol deviations will not be 
prospectively granted by the sponsor. If deviations occur, such as a visit or sampling window 
being missed, the investigator must decide whether to proceed, for example, whether or not 
to complete the visit or samp le collection outside of the protocol -defined window. The 
sponsor’s medical monitor must be notified immediately when protocol deviations are 
discovered so that a decision about whether to keep the subject in the study can be made.  
Only when an emergency o ccurs that requires a departure from the protocol for an individual 
subject will there be such a departure without the sponsor’s pre -approval. The nature and 
reasons for the protocol deviation will be recorded in the subject’s CRF, and the principal 
invest igator must notify the Sponsor.  
Protocol violations must be reported in the final study report.  
10.9 Access to Source Documentation  
Authorized sponsor representatives will conduct site visits to inspect study data, subjects’ 
medical reco rds, and CRFs in accordance with ICH guidelines, GCPs, and the respective 
local and national government regulations and guidelines.  
The investigator will permit authorized representatives of the sponsor and the respective 
national or local health authoriti es, other authorized regulatory authorities, and IRB/IEC to 
inspect facilities and records relevant to this study.  
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 44 of 48 The center will be visited at regular intervals by a monitor to ensure compliance with the 
study protocol, GCP, and legal aspects. This will include on -site checking of the CRFs for 
completeness and clarity, cross -checking with source documents, and clarification of 
administrative matters.  
All CRF data will be entered into a clinical database. Following the correction of any errors, 
the clinica l database will be locked.  
10.10  Retention of Data  
The study file and all source data should be retained until notification is given by the sponsor 
for destruction.  
If the investigator withdraws from the trial and relinquishes his/her responsibility for the 
main tenance and retention of records, he/she must notify the sponsor in writing so that 
arrangements can be made to properly store the trial materials.  
10.11  Publication and Disclosure Policy  
All data and results and all intellectual -property rights in the data and results derived from 
the study will be the property of the sponsor, who may utilize the data in various ways, such 
as for submission to government regulatory authorities or disclosure to other investigators.  
No publication or disclosure of study results wi ll be permitted except as specified in a 
separate, written agreement between Theracos Sub, LLC  and the investigator. If results of 
this study are reported in medical journals or at meetings, all subjects’ identities will remain 
confidential.  
 
 
 
 
 
 
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 45 of 48 11 REFEREN CE LIST  
Food Drug Administration, H. H. S. (2002). "Guidance for Industry Food -Effect 
Bioavailability and Fed Bioequivalence Studies."  
 
Washburn, W. N. (2009). "Evolution of sodium glucose co -transporter 2 inhibitors as anti -
diabetic ag ents." Expert Opin Ther Pat  19(11): 1485 -1499.  
 
Zhang, W., A. Welihinda, J. Mechanic, H. Ding, L. Zhu, Y. Lu, Z. Deng, Z. Sheng, B. Lv, Y. 
Chen, J. Y. Roberge, B. Seed and Y. X. Wang (2011). "EGT1442, a potent and selective 
SGLT2 inhibitor, attenuates bloo d glucose and HbA(1c) levels in db/db mice and prolongs 
the survival of stroke -prone rats." Pharmacol Res  63(4): 284 -293. 
 
 
Theracos Sub, LLC.  Bexagliflozin,  20 mg 
Clinical Trial Protocol : THR -1442 -C-481  20 May 2016  
   
 
Confidential  Page 46 of 48 Appendix 1  Schedule of Events  
 Screening  Period 1  Period 2  
Study activity  D -28 to -
1 D0 D1  
pre-
dose  D1  
post-
dose  D2 D3 D7 D8  
pre-
dose  D8  
post-
dose  D9 D10 
Medical history and ICF  X           
Screening for I/E criteria1 X X     X     
Physical exam2 X X         X 
Demographics  X           
Randomization   X          
Admission and discharge   X    X X    X 
Vital signs3 X  X X  X  X X  X 
ECG4 X  X X    X X  X 
Urinalysis5 X  X   X  X   X 
Blood draw for clinical lab 
tests6 X  X   X  X   X 
Blood sample for PK7   X X X X  X X X X 
Urine Collection8  X X X X X X X X X X 
Urine Pregnancy Test  X           
Adverse event and 
concomitant medication   X X X X X X X X X X 
Study termination            X 
1. Subject compliance with inclusion and exclusion criteria will be verified  at check -in of each period (on 
day 0 and day 7).  
2. Weight and height will be recorded as part of the physical examinati on. Height will be recorded once 
at screening only. A complete physical exam (PE) will be performed at screening and day 10 prior to 
discharge . 
3. Vital signs include: pulse, body temperature, respirat ion rate, systolic and diastolic blood pressure. On 
days 1 and 8, vital signs will be determined at pre -dose and at 4 h and 48 h (day 3 or 10) post -dose.  
4. 12-lead ECG will be conducted after 10 min of rest. ECG data will be recorded at screening, on days 1 
and 8 at pre -dose and at 4 h post -dose and  when clinicall y indicated.  
5. Clean sample to be collected at each visit. If urine is dipstick positive for leukocyte esterase or nitrites , 
sample is to be sent for microscopic evaluation and culture. Urine drug screen will be performed on 
screening visit  only. If screenin g is conducted more than 5 days prior to dosing, drug screening shall be 
repeated.  
6. Blood sample s at the designated visits for clinical chemistry and hematology parameters are listed in 
Table  2. 
7. Plasma samples for the PK profile of  bexagliflozin  will be collected at  pre-dose and at 1, 2, 3, 4, 5, 6, 
8, 10, 12, 16, 24, 36, and 48 h post -dose.  
8. Urine collection for urinary glucose (PD), electrolytes, uric acid & creatinine are described in Section 
6.6.2.3.  
 
 
 
 